Health officials are monitoring a new variant of the virus that causes COVID-19, dubbed “Cigarra” or BA.3.2, as it spreads across several countries. While not currently believed to cause more severe illness, the variant’s ability to evade existing immunity is raising concerns among researchers. As of February 11, 2026, the Centers for Disease Control and Prevention (CDC) reports that the variant has been identified in 23 countries, prompting increased surveillance and analysis.
The emergence of “Cigarra” underscores the ongoing evolution of the virus and the continued require for vigilance. Scientists emphasize that while the current risk to public health appears low, the variant’s characteristics warrant close observation. This new lineage, like previous variants, highlights the virus’s capacity to mutate and potentially circumvent the protection offered by prior infection and vaccination.
Origins and Spread of the “Cigarra” Variant
The “Cigarra” variant is a sublineage of Omicron, first identified in South Africa in late 2024. It subsequently spread to various regions throughout 2025 and 2026, according to the CDC. Researchers have noted a significant number of mutations within the variant, particularly in the spike protein – a key component of the virus responsible for its ability to infect cells. These changes in the spike protein are believed to contribute to its increased ability to evade immunity.
The World Health Organization (WHO) began monitoring “Cigarra” in December 2025, and currently confirms that no cases have been detected in Mexico. Confirmed cases have been reported in the following countries:
- Africa: South Africa, Mozambique, Kenya
- Europe: Netherlands, Germany, Denmark, United Kingdom
- Asia: Japan
- Americas: United States
Symptoms of the “Cigarra” Variant
Current data suggests that the symptoms associated with the “Cigarra” variant are similar to those of other COVID-19 strains and common respiratory illnesses. Reported symptoms include:
- Fever
- Dry cough
- Sore throat
- Fatigue
- Headache
- Nasal congestion or runny nose
- Muscle aches
The CDC notes that the general symptoms of the new COVID-19 variant can easily be confused with other respiratory illnesses, making accurate diagnosis challenging. Individuals experiencing these symptoms are advised to consult a healthcare professional, even if their symptoms appear mild. Early detection and appropriate medical guidance can assist prevent further spread and ensure timely care.
Vaccine Effectiveness and Immune Evasion
Scientists at the CDC have confirmed that existing COVID-19 vaccines may offer reduced protection against infection with the “Cigarra” variant due to its immune-evading properties. Whereas, vaccination continues to be a critical tool in mitigating severe illness, hospitalization, and death. While breakthrough infections are more likely with this variant, vaccinated individuals generally experience milder symptoms and a lower risk of serious complications.
“Vaccines are still our best defense against severe outcomes from COVID-19,” explains Dr. Maria Van Kerkhove, the WHO’s technical lead on COVID-19, in a recent press briefing. The WHO continues to emphasize the importance of staying up-to-date with recommended vaccinations and boosters.
Ongoing Monitoring and Future Outlook
The “Cigarra” variant is under close international surveillance, with health organizations worldwide collaborating to track its spread and assess its potential impact. Researchers are actively studying the variant’s genetic characteristics, transmissibility, and response to existing treatments and vaccines. The WHO reported that the variant experienced rapid spread beginning in September 2025, peaking in December of that year.
The CDC is also working to improve diagnostic testing to more accurately detect the “Cigarra” variant and differentiate it from other circulating strains. This will be crucial for informing public health interventions and guiding clinical decision-making.
As the virus continues to evolve, public health experts stress the importance of maintaining preventative measures, including practicing great hygiene, wearing masks in crowded indoor settings, and staying home when sick. Continued research and global collaboration will be essential to effectively manage the ongoing threat of COVID-19 and its emerging variants.
Disclaimer: This information is for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The situation surrounding the “Cigarra” variant remains fluid. The CDC and WHO are expected to provide updated information and guidance as new data becomes available. Stay informed by checking their official websites for the latest developments.
Share your thoughts and questions in the comments below. And please, share this article with your network to help keep everyone informed.
